Medicine & Life Sciences
Breast Neoplasms
100%
Tamoxifen
33%
Triple Negative Breast Neoplasms
31%
4-hydroxy-N-desmethyltamoxifen
29%
5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzimidazol-5-yl)pyrimidin-2-yl)amine
26%
Neoplasms
23%
Drug Therapy
20%
Cytochrome P-450 CYP2D6
19%
Aromatase Inhibitors
19%
Anastrozole
18%
Estrogen Receptors
17%
Hormones
17%
human ERBB2 protein
17%
Therapeutics
16%
Pharmacogenetics
13%
Recurrence
12%
Estrogens
11%
Disease-Free Survival
10%
Trastuzumab
9%
Heterografts
9%
Single Nucleotide Polymorphism
9%
Estrogen Receptor beta
9%
Lapatinib
8%
palbociclib
8%
Survival
8%
Fulvestrant
8%
Tumor-Infiltrating Lymphocytes
8%
Oxaliplatin
8%
Biomarkers
8%
Genotype
8%
Guidelines
7%
exemestane
7%
Breast
7%
Neoplasm Metastasis
7%
Irinotecan
7%
Cyclin-Dependent Kinase 6
6%
Progression-Free Survival
6%
Letrozole
6%
Cyclin-Dependent Kinase 4
6%
Clinical Trials
6%
Genome-Wide Association Study
6%
Adjuvant Chemotherapy
5%
Genes
5%
Pharmaceutical Preparations
5%
Safety
5%
Pharmacokinetics
5%